Dandelion Health Launches Clinical AI Marketplace to Combine Multimodal RWD with Validated AI
Dandelion Health’s Clinical AI Marketplace Shows GLP-1s May Help Prevent Cardiovascular Disease for 44 Million Previously Unstudied U.S. Patients
Dandelion layered validated, unbiased AI from its new Clinical AI Marketplace against its real-world data to demonstrate the potential preventive impact of the GLP-1 drug class for a 7x larger population than those previously studied
NEW YORK CITY, September 18, 2024 – Dandelion Health, a real-world data (RWD) and clinical AI platform powering next-generation precision medicine and personalized care, announced results today from a large study that demonstrated that GLP-1 medications may be effective as primary prevention for cardiovascular disease (CVD) for 44 million additional at-risk patients who have not been studied until now. The study was conducted using validated AI accessible on Dandelion’s Clinical AI Marketplace, which also officially launched today.
Dandelion’s Clinical AI Marketplace enables life sciences organizations to conduct novel scientific research at a fraction of the time and cost of a clinical trial — and far more comprehensively than using traditional RWD typically limited to structured data. Dandelion’s Marketplace also hosts AI algorithms sourced from a rapidly growing ecosystem of clinical AI developers. The company validates those algorithms for performance and equity and runs them on robust, representative RWD to generate rapid, novel insights that researchers can analyze along with all other patient data.
Even though it has an extremely high value, as much as 80% of RWD is unstructured and inaccessible — and found in formats like imaging files, waveforms, and raw clinical notes. Provider notes can, for example, shed light on reasons for treatment discontinuation or symptoms. Medical images (like CTs and MRs) and waveforms can reveal in-depth changes resulting from a new treatment. Dandelion’s Marketplace interprets this siloed data and makes it accessible.
To demonstrate the power of the Clinical AI Marketplace, Dandelion conducted an observational research study to examine a key research question unstudied in clinical trials: Can GLP-1s serve as a primary prevention tool and reduce the risk of heart attacks and strokes among those who do not yet suffer from severe cardiovascular disease?
Dandelion’s study required less than 1% of the time and cost of the clinical trial and was produced in just six weeks using its GLP-1 data library, including a far broader population than possible in clinical trials. For example, Novo Nordisk’s SELECT trial, which demonstrated how semaglutide can reduce major adverse cardiovascular events (MACE), was narrowly focused on obese, non-diabetic adult patients with preexisting severe CVD. Dandelion’s study considered “clinically silent” patients not included in this trial — i.e., those without a past adverse cardiovascular disease event or evidence of preexisting severe cardiovascular disease.
Dandelion used AI to de-risk and accelerate its clinical research. In order to study GLP-1s’ cardioprotective benefits, Dandelion used an AI-biomarker algorithm developed by Pheiron that predicts the risk of MACE using raw ECG waveforms collected during regular clinical care. The company also leveraged its public validation service to ensure the algorithm was high-performance and unbiased.
“The combined power of real-world data and AI has the potential to reshape how life sciences conduct clinical trials and research,” said Shivaani Prakash, MSc, PhD, Head of Data at Dandelion Health. “By combining diverse, multimodal data with validated AI, life sciences companies and researchers can now study treatment effects on a far larger, more representative population — and do so at a fraction of the cost and time.”
In this study, for example, Dandelion used AI to model predicted MACE risk reduction from GLP-1s, rather than wait for adverse events to actually occur. Its findings indicate that GLP-1s result in 15%–20% lower MACE risk among patients after three years, as compared to similar patients not taking GLP-1s. A previously unstudied population of 44 million additional patients may experience these cardioprotective benefits1. If this broader group of patients were to take a GLP-1, this could potentially result in 34,000 fewer myocardial infarctions and strokes annually.
“The cost and time associated with drug development and commercialization are substantial, but the impact of providing the right treatment to the right patient, and doing so with unprecedented speed, is immeasurable for the billions of people who depend on innovative drugs and therapies,” said Elliott Green, Co-founder and CEO of Dandelion Health.
Similar research may enable life sciences companies to de-risk future clinical trials, compare various treatments head-to-head, and support market access and reimbursement decisions. These types of insights also enable providers to select the right treatment for their patients at the right time, enabling earlier intervention and reducing avoidable adverse health outcomes.
To learn more, download our white paper created using the Clinical AI Marketplace
About Dandelion Health
Dandelion Health is a real-world data (RWD) and clinical AI platform powering next-generation precision medicine and personalized care. Dandelion’s platform delivers novel clinical insights at scale from rich, multimodal patient data - enabling AI, medical device and life sciences companies to accelerate the entire product development lifecycle, improving clinical outcomes and enhancing patient lives. Founded by the world’s leading experts in healthcare and AI, Dandelion is a diverse and growing consortium of leading healthcare systems from across the United States.
